BFM
ITCI

Boothbay Fund Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Boothbay Fund Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,900
Closed -$823K – 1915
2024
Q1 		$823K Buy
+11,900
New +$818K 0.02% 813
2023
Q2 		– Sell
-78,800
Closed -$4.27M – 2403
2023
Q1 		$4.27M Buy
+78,800
New +$3.81M 0.09% 307
2022
Q2 		– Sell
-5,400
Closed -$330K – 2746
2022
Q1 		$330K Buy
+5,400
New +$280K 0.01% 1556
2021
Q3 		– Sell
-23,200
Closed -$947K – 2252
2021
Q2 		$947K Buy
23,200
+22,968
+9,900% +$849K 0.03% 723
2021
Q1 		$787K Buy
+232
New +$8.05K 0.03% 723
2020
Q4 		– Sell
-281
Closed -$721K – 1460
2020
Q3 		$721K Sell
281
-296
-51% -$6.75K 0.04% 536
2020
Q2 		$1.48M Buy
+577
New +$11.7K 0.1% 270
2020
Q1 		– Sell
-449
Closed -$1.54M – 1107
2019
Q4 		$1.54M Sell
449
-580
-56% -$6.96K 0.13% 208
2019
Q3 		$769K Buy
+1,029
New +$9.87K 0.07% 364
2019
Q2 		– Sell
-300
Closed -$365K – 928
2019
Q1 		$365K Buy
+300
New +$3.83K 0.04% 458

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Boothbay Fund Management's ITCI Position: Q2 2025 in Review

Boothbay Fund Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 63,819 shares — an estimated $8.42M sold.

Boothbay Fund Management first reported a position in ITCI in Q4 2016 and held it in 11 quarters. The position peaked at $8.42M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Boothbay Fund Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 63,819 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $8.42M.
  • Boothbay Fund Management first reported a position in Intra-Cellular Therapies Inc. in Q4 2016 and held it in 11 quarters.
  • Boothbay Fund Management's Intra-Cellular Therapies Inc. position peaked at $8.42M in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Boothbay Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.